THE RELATIONSHIP BETWEEN SERUM OSTEOPROTEGERIN LEVELS AND CLINICAL, PARACLINICAL CHARACTERISTICS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

Văn Tuấn Nguyễn, Đức Hùng Trần, Công Thức Lương

Main Article Content

Abstract

Objectives: To investigate the relationship between serum OPG levels and clinical, paraclinical characteristics in patients with acute myocardial infarction (AMI). Methods: We enrolled 135 acute MI patients underwent percutaneous coronary intervention at Cardiovascular Intervention Department – 103 Military Hospital from 02/2021 to 04/2023 and 50 control subjects without coronary artery disease. Testing serum OPG levels at the time of admission, evaluating the relationship between OPG levels and clinical, paraclinical characteristics. Result: OPG concentration in patients with AMI was significantly higher than that in the control group (2323.63 ± 2276.23 pg/ml vs. 1424.24 ± 456.74 pg/ml, p < 0,001). In the MI group, patients admitted early (≤ 12h) had signficantly lower OPG concentrations than patients admitted late (> 12h); levels of serum OPG had a strong positive correlation with age (r = 0.527, p < 0.001), a moderate positive correlation with Troponin I (r = 0,346, p < 0.001), CK – MB (r = 0,323, p < 0.001) and NT-proBNP (r = 0.337, p < 0.001). Patients with multivessel coronary artery lesions had significantly higher OPG levels than those with single vessel lesions (2450.37 ± 696.99 vs 2127.53 ± 664.49 pg/ml, p < 0.05). Conclusion: Patients admitted early (≤ 12h) had signficantly lower OPG concentrations than patients admitted late (> 12h). Levels of serum OPG had a positive correlation with age, Troponin I, CK-MB and NT-proBNP. Patients with multivessel coronary artery lesions had significantly higher OPG levels than those with single vessel lesions.

Article Details

References

Omland, T., et al., Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol, 2008. 51(6): p. 627-33.
2. Crisafulli, A., et al., Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond), 2005. 109(4): p. 389-95.
3. Roysland, R., et al., Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart, 2012. 98(10): p. 786-91.
4. Thygesen, K., et al., Fourth Universal Definition of Myocardial Infarction (2018). Circulation, 2018. 138(20): p. e618-e651.
5. Hosbond, S.E., et al., Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings? Atherosclerosis, 2014. 236(2): p. 230-6.
6. Omland, T., et al., Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension, 2007. 49(6): p. 1392-8.
7. Cottin, Y., et al., Association between Serum Osteoprotegerin Levels and Severity of Coronary Artery Disease in Patients with Acute Myocardial Infarction. J Clin Med, 2021. 10(19).
8. Jono, S., et al., Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 2002. 106(10): p. 1192-4.